RARE
NASDAQ · Biotechnology
Ultragenyx Pharmaceutical In
$14.51
+0.01 (+0.07%)
RARE News3 articles
Ultragenyx Soars 12.6% on FDA Full Approval of Gene Therapy FAYUVI
Ultragenyx shares surged 12.6% after FDA full approval of FAYUVI, a gene therapy for Sanfilippo syndrome type A. The company plans to launch within 30-60 days.
Oil Surges Past $92, Tech Futures Dip as Energy Gains Outweigh AI Optimism
Crude oil climbs above $92 a barrel, erasing earlier tech gains. Snowflake jumps 24% on strong results, while Ultragenyx drops 44% after a failed trial.
Ultragenyx Plunges 44% as Angelman Gene Therapy Fails Phase 3 Trial
Ultragenyx's stock plummeted 44% after its Phase 3 apazunersen trial failed, wiping out $1.14 billion in market cap. The company now faces major cost cuts.